Key Highlights
- Indoco Remedies has approved the transfer of its ophthalmic division in India and agreed territories in Africa to Sunways (India) Private Limited under an Agreement to Transfer Business (ATB), marking a strategic divestment aimed at sharpening Indoco’s focus on core therapeutic areas with higher growth potential
- The transaction is expected to strengthen Sunways’ ophthalmology platform by adding an established operating business that complements its existing ophthalmic and ENT portfolio as well as its sterile manufacturing capabilities
- Sunways (India) Private Limited, the flagship company of the Sunways group, manufactures and markets formulations in ophthalmology and ENT, with capabilities spanning sterile ophthalmic products, ENT preparations, oral medications, and other sterile formulations
Implications:
Indoco is effectively cashing out of a non-core, lower-scale ophthalmic franchise (₹110 crore slump sale) to refocus capital and management on higher-growth domestic and international formulations, while tightening its portfolio around priority therapies.
For Sunways, the deal is a strategic bolt-on: it folds an established branded ophthalmic business and field force into an already focused eye/ENT platform with strong sterile capacity, deepening its presence in Indian and select African eyecare markets and strengthening its positioning as a specialist partner for ophthalmologists and ENTs.
Source: Indoco | Image: Indoco
No Comment! Be the first one.